Exploring the Clinical Performance of Disitamab Vedotin-Keytruda Combination in Bladder Cancer

  • Building on the past success of ADC-immunotherapy combination therapies
  • Contextualizing Disitamab Vedotin-immunotherapy success in bladder cancer
  • Outlining additional clinical DV-IO combination response in bladder cancer